Parkinson’s Disease

AbbVie Inc (NYSE: ABBV) has advanced its collaboration with privately-held Mission Therapeutics, with the nomination of two DUB targets to take into the next stage of drug discovery. This selection follows supportive data from in vitro and in vivo Alzheimer's and Parkinson...

Clene Inc (NASDAQ: CLNN) has shared positive top-line results from the Phase 2 REPAIR trials investigating the improvement of brain energetic metabolism in Parkinson's disease (PD) and multiple sclerosis (MS). The objective of the REPAIR program was to demonstrate the effects of...

In 2000, actor Michael J. Fox launched The Michael J. Fox Foundation (MJFF) for Parkinson’s Research and became one of the most well-known spokesmen for finding a cure for the condition. What To Know: A partnership between the MJFF has been launched with International Business Machines Corp (...

AC Immune SA (NASDAQ: ACIU) has gained a multi-million investment from the principal backers of BioNTech SE (NASDAQ: BNTX) while acquiring a possible Parkinson's disease vaccine. It announced a $25 million private share placement with a group of investors led by Athos...

The FDA has signed off Inhibikase Therapeutics Inc's (NASDAQ: IKT) Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's patients. The randomized Phase 1 study investigated the safety, tolerability, and pharmacokinetics (PK) of IkT-148009 in...

Acorda Therapeutics Inc (NASDAQ: ACOR) has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A. to commercialize Inbrija 33 mg (levodopa inhalation powder, hard capsules) in Spain.  Inbrija is indicated in the E.U. for the intermittent...

Ipsen SA (OTC: IPSEY) and IRLAB have signed a licensing agreement, providing Ipsen exclusive rights to mesdopetam.  Under the terms of the agreement, IRLAB will be eligible to receive up to $363 million, including an upfront cash payment of $28 million and up to $335...

Seelos Therapeutics Inc (NASDAQ: SEEL) has announced positive in vivo data demonstrating down-regulation of SNCA mRNA and protein expression from a study of SLS-004. The SNCA gene has been implicated as a highly significant genetic risk factor for Parkinson's Disease (PD). In...

Addex Therapeutics Ltd (NASDAQ: ADXN) has started patient screening for its Phase 2b/3 study evaluating dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID).  Dyskinesia is believed to be caused by increased glutamatergic neurotransmission. ...

Anavex Life Sciences Corp (NASDAQ: AVXL) has reported that SIGMAR1 mRNA expression correlates positively with responses in efficacy endpoints in the Phase 2 trial of ANAVEX 2-73 (blarcamesine) in patients with Parkinson's disease dementia. ANAVEX 2-73 activates the sigma-1...

Caraway Therapeutics has entered into an exclusive collaboration and option agreement with AbbVie Inc (NYSE: ABBV) to develop and commercialize Caraway's small molecule therapeutics targeting TMEM175. Loss of function mutations in TMEM175 is associated with reduced...

The FDA recently rejected an attempt by Alphabet Inc’s (NASDAQ: GOOG) (NASDAQ: GOOGL) Verily in its efforts to add a Parkinson’s disease symptom assessment to its clinical research-focused smartwatch. Verily Study Watch is a sensor-based wearable device...

Bayer AG’s (OTC: BAYRY) Parkinson’s disease stem cell therapy has officially landed in the clinic, while another treatment for the neurodegenerative movement disorder is recruiting patients. Bayer’s subsidiary BlueRock Therapeutics’s trial will...

Annovis Bio Inc (NYSE: ANVS) has announced preliminary data demonstrating that ANVS401 protects certain nerve cells from dying after being infected by gingipains, which has a potential role in developing Alzheimer's Disease. At the concentration of 1nM gingipain, infected cells were...

Annovis Bio Inc (NYSE: ANVS) has announced new results from a Phase 2 study evaluating its lead drug candidate, ANVS401, for Alzheimer's disease (AD), Parkinson's disease (PD). The data comes from 14 AD patients and 14 PD patients. Participants treated with ANVS401 for 25...